Swiss National Bank’s Avadel Pharmaceuticals AVDL Stock Holding History

Swiss National Bank’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-172,400	Closed	-$3.72M	–	2308
2025 Q4	$3.72M	Buy	172,400 +4,400	+3%	+$85.4K	﹤0.01%	1525
2025 Q3	$2.57M	Hold	168,000	–	–	﹤0.01%	1724
2025 Q2	$1.49M	Hold	168,000	–	–	﹤0.01%	1957
2025 Q1	$1.32M	Sell	168,000 -2,400	-1%	-$20.1K	﹤0.01%	2006
2024 Q4	$1.79M	Buy	170,400 +20,200	+13%	+$245K	﹤0.01%	1921
2024 Q3	$1.97M	Buy	+150,200	New	+$2.29M	﹤0.01%	1866

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Swiss National Bank's AVDL Position: Q1 2026 in Review

Swiss National Bank sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 172,400 shares — an estimated $3.72M sold.

Swiss National Bank first reported a position in AVDL in Q3 2024 and held it in 6 quarters. The position peaked at $3.72M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Swiss National Bank reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Swiss National Bank sold 172,400 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.72M.
Swiss National Bank first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 6 quarters.
Swiss National Bank's Avadel Pharmaceuticals position peaked at $3.72M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.